Neprilysin Modification of Amyloid Processing in Models of AD

$253,715P01FY2014AGNIH

University Of California, San Diego, La Jolla CA

Investigators

Linked publications, trials & patents

Paper 29535375 Paper 29045838 Paper 28130011 Paper 28067668 Paper 27558862 Paper 27525439 Paper 27466341 Paper 27419933 Paper 26948893 Paper 26903653 Paper 26620558 Paper 26489892 Paper 26388203 Paper 26341908 Paper 26302439 Paper 26202279 Paper 25803611 Paper 25788688 Paper 25673831 Paper 25533483 Paper 25505106 Paper 25448159 Paper 25173807 Paper 25126588 Paper 25093680 Paper 25024337 Paper 25022790 Paper 24885390 Paper 24825898 Paper 24813892 Paper 24462903 Paper 24068826 Paper 23935974 Paper 23626796 Paper 23413261 Paper 23401561 Paper 23392688 Paper 23384597 Paper 23313024 Paper 23254192 Paper 23223568 Paper 23182244 Paper 23152192 Paper 22989354 Paper 22833673 Paper 22810100 Paper 22647715 Paper 22528101 Paper 22514658 Paper 22508489 Paper 22492998 Paper 22456708 Paper 22314685 Paper 22281106 Paper 22229116 Paper 22211740 Paper 22150925 Paper 22112803 Paper 22066148 Paper 22064070 Paper 21998872 Paper 21994367 Paper 21928509 Paper 21860085 Paper 21403389 Paper 21368891 Paper 21358740 Paper 21304989 Paper 21296890 Paper 21257908 Paper 21103359 Paper 21045796 Paper 20970422 Paper 20679195 Paper 20559548 Paper 20554871 Paper 20445049 Paper 20433905 Paper 20413653 Paper 20181623 Paper 20140000 Paper 20091183 Paper 19944097 Paper 19932737 Paper 19931251 Paper 19864570 Paper 19726646 Patent 7674455 Patent 7328129 Patent 7244423 Patent 7157435 Patent 7101540 Patent 6998118 Patent 6875569 Patent 6815431 Patent 6683058 Patent 6680292 Patent 6451306 Patent 6300488 Patent 5919667

Abstract

PROJECT SUMMARY (See instructions): This is the second re-submission of the competitive renewal. Accumulation of Aß early in AD appears to play an important role in the mechanisms of synaptic damage and neurodegeneration leading to cognitive deficits. During the previous period of funding we focused at developing new models and treatments for AD using lentiviral vectors expressing or blocking Aß degrading enzymes such s neprilysin (NEP). NEP might be important for AD also because its possible involvement in neuroprotection and as an interface between environment and genetic regulation of synaptic plasticity responses. NEP cleaves bioactive transmitters such as Neuropeptide Y (NPY) resulting in trophic C-terminal fragments (CTFs). In this context, we hypothesize that among other AB-degrading enzymes, NEP might be involved in neuroprotection in APP transgenic (tg) mice by regulating synaptic remodeling and neurogenesis in the hippocampus. The main objective of this collaborative competitive renewal will be to investigate the molecular mechanisms through which interactions between environment and Aß-degrading enzymes regulate synaptic regeneration and neurogenesis during aging and in AD. To this end we propose the following: Aim 1. To determine the Aß-independent effects of NEP and other Aß-degrading enzymes in synaptic regeneration during aging to murine models. Aim 2. To investigate the molecular mechanisms through which Aß-degrading enzymes regulate synaptic regeneration during aging and in APP tg models of AD. Aim 3. To investigate the combined effects of physical activity and expression of Aß-degrading enzymes on neurogenesis during aging and in APP tg models of AD. Aim 4. To evaluate the potention therapeutical and neuroprotective effects of NPY fragments in APP tg models of AD. In collaboration with the Cores with will perform studies of synaptic plasticity, neurogenesis and enhanced physical activity in APP tg, NEP, APP and NPY deficient mice, treated with lentiviral vectors expressing Aß-degrading enzymes and NPY fragments. Together, these studies might also help in develop new treatments for AD that will have the dual role of reducing accumulation of neurotoxic Ab species and promoting neurogenesis.

View original record on NIH RePORTER →